DNA Polymerase β as a Novel Target for Chemotherapeutic Intervention of Colorectal Cancer
2011

Targeting DNA Polymerase β to Improve Colorectal Cancer Treatment

publication 10 minutes Evidence: moderate

Author Information

Author(s): Jaiswal Aruna S., Banerjee Sanjeev, Aneja Ritu, Sarkar Fazlul H., Ostrov David A., Narayan Satya

Primary Institution: University of Florida

Hypothesis

Can the small molecule NSC-124854 enhance the efficacy of the DNA-alkylating agent Temozolomide in treating colorectal cancer by blocking the base excision repair pathway?

Conclusion

The study found that NSC-124854 effectively enhances the sensitivity of both MMR-deficient and MMR-proficient colon cancer cells to Temozolomide.

Supporting Evidence

  • NSC-124854 was identified as a potent inhibitor of Pol-β activity.
  • Combination treatment with NSC-124854 and Temozolomide significantly reduced tumor growth in both MMR-deficient and MMR-proficient colon cancer models.
  • NSC-124854 showed high specificity for Pol-β and did not inhibit other BER enzymes.

Takeaway

Researchers found a new drug that helps make cancer treatment more effective by blocking a repair process in cancer cells, allowing a common chemotherapy drug to work better.

Methodology

The study used in silico molecular docking to identify NSC-124854 and tested its effects on Pol-β activity and its ability to enhance the efficacy of Temozolomide in various colon cancer cell lines and xenograft models.

Limitations

The study did not determine the maximum tolerated dose of NSC-124854 in vivo, and the results may not fully translate to clinical settings.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016691

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication